Summary.-The urinary excretion during 24 h of aminoglutethimide (AG) its major metabolite (N-acetylAG) and two minor metabolites (N-formylAG and nitroG) were measured in 10 volunteers given AG who had been typed for acetylator phenotype using sulphadimidine. The slow acetylators of sulphadimidine excreted more AG (mean 28% of the administered dose) than did the fast acetylators (12%), but the latter excreted more of the dose as N-acetylAG (8.8%) than did the former (3.9O%).
AMINOGLUTETHIMIDE (Elipten, CIBA, Horsham: AG) is an effective agent in the treatment of mammary carcinoma in postmenopausal women (Smith et al., 1978) . It acts by inhibiting adrenal steroidogenesis, thereby effecting a "medical adrenalectomy". N-AcetylAG (Douglas & Nicholls, 1972) is the major urinary metabolite in humans, accounting for 4-25% of the administered dose. Compared with AG, the N-acetyl derivative is a poor inhibitor of steroidogenesis, as measured by ability to reduce corticosteroid output in bovine adrenal cells in culture. Thus, 10 jg/ml of the parent compound reduced glucocorticoid production to 833% of the resting levels, whereas this concentration of the N-acetylated compound reduced it only to 58% of resting levels (Coombes et al., 1980) . From the therapeutic viewpoint, therefore, Nacetylation represents adverse metabolism of AG, and it becomes important to consider the extent to which N-acetylation prejudices the therapeutic effectof the drug. N-Acetylation of many drugs is genetically controlled in humans and other species, a bimodal distribution into rapid and slow acetylators being observed (Price-Evans & White, 1964) . Acetylation is not invariably polymorphic. Thus, whereas isoniazid, sulphamethazine and diaminodiphenylsulphone are polymorphically acetylated in humans, p-aminobenzoic acid and sulphanilamide are not (Testa & Jenner, 1976) . Where the drug and its N-acetyl derivative differ in therapeutic efficacy or in their side effects, response may depend upon acetylator phenotype. Thus both procainamide (Woosley et al., 1978) and hydralazine (Perry et al., 1970) induced the adverse side-effect of lupus erythematosus, preponderantly in those subjects who were slow acetylators, implicating the parent drug as the cause of this reaction.
AG also frequently elicits side effects in patients, in particular skin rash and lethargy (Smith et al., 1978) . The sedative effect is dose-limiting and is not dependent on the presence of the amino function since the parent drug, glutethimide (Doriden, CIBA), which has little inhibitory effect on steroidogenesis, is a powerful hypnotic (Hoffman & Tagmann, 1954) . Should NacetylAG also possess hypnotic activity, any factor which depletes this metabolite may improve the therapeutic effect without simultaneously augmenting the hypnotic activity. Hence it is relevant to consider whether AG is polymorphically acetylated, as the first step to assessing the significance of N-acetylation in the therapeutic and toxic effects of this drug in humans.
N-FormylAG and nitroG are additional, though minor urinary metabolites of AG in humans (Baker et al., 1981 N-acetylAG (T 11.0 min), N-formylAG (T 9-2 min) and nitroG (T 28-4 min) were detected and characterized by mass spectrometry (Baker et al., 1981) and comparison with authentic compounds. N-AcetylAG and nitroG were obtained by published methods (Aboul-Enein et al., 1975) ; the preparation of N-formylAG is described below. ComponerAts were quantified by peak area with reference to the responses to known quantities of the authentic compounds.
Synthesis of N-formylAG.-A solution of AG (232 mg; 1 mmol) in formic acid (1 ml) was stored for 30 min at room temperature,
concentrated to dryness, and the residue was crystallized from water-2-propanol, (9:1) to yield the N-formyl derivative as colourless crystals (160 mg, 61°%) m.p. 138-140°C.
Calculated for C14H16;N203:C, 65-5; H, 5-9; N, 11.8%. Found: C, 65-6; H, 6-2; N, 11.8%.
RESULTS
Acetylator phenotype for sulphadimidine and AG
The volunteers divided equally into (Fig. 2b) was greater for the rapid acetylators.
DISCUSSION
The present study affords compelling evidence that AG is polymorphically acetylated in humans. The results amplify and confirm preliminary evidence for polymorphic acetylation, based on plasma levels of AG and its N-acetyl derivative in these subjects. Thus Coombes et al. (1980) found that levels of N-acetylAG at 0O5, 2 and 8 h were significantly higher in the 5 rapid acetylators (means of 1 06, 1 22 and 1 05 Kg/ml respectively) than in the 4 slow acetylators who were evaluated (means of 0O50, 0 61 and 0-37 ,ug/ml respectively). However, the levels of AG in the rapid acetylators (0.96, 0-60 and 0*85 jig/ml) and in the slow acetylators (1.14, 1*10 and 0 07 xg/ml) did not differ significantly. The present studies on the urinary levels were not performed concurrently with the plasma determinations because, in the HPLC analysis, it was necessary to replace the linear tripartite gradient between 20-50% aqueous methanol used for the plasma measurements with the present isocratic system. The urinary levels of AG also showed some 24 overlap between the rapid and the slow acetylator phenotypes, implying that the bimodal distribution is less marked for the acetylation of AG than of sulphadimidine. The bimodal distribution in the output of the minor metabolite nitroG deserves comment. Formation of nitro derivatives from their amino precursors is an unusual metabolic transformation which probably proceeds via an intermediate hydroxylamino derivative. Thus both types of compound have been isolated after microsomal metabolism of 4,4'-diaminodiphenylsulphone (Tyler et al., 1973; Tabarelli & Uehleke, 1971) but it is possible that the second step (hydroxylamino---nitro) takes place non-enzymatically, both in the cited example and in the present case. Although polymorphism of drug oxidation in man has also been observed (Eichelbaum, 1981) it is unnecesa) CO) 0 0O sary to invoke it in order to explain the distribution in nitroG levels. Thus the rapid acetylators could excrete less nitroG simply because the pool of AG available for alternative pathways is depleted in these subjects. Therefore bimodal distribution in nitroG execretion is probably a reflection of acetylator phenotype.
The absence of a bimodal distribution in the excretion of N-formylAG requires explanation, since on the foregoing argument this component should also be depleted in the urine of rapid acetylators. Formylation is also an infrequently observed metabolic transformation, and Stillwell et al. (1978) have cautioned that it can occur artifactually by reaction between basic -NH functions and phosgene generated from chloroform (and implicitly from dichloromethane). However, this origin for N-formylAG was discounted, since dichloromethane extracts of urine containing known amounts of AG (used to construct standard curves) contained none of the Nformyl derivative as evidenced by HPLC analysis. Formylation is mediated by the enzyme kynurenine formamidase (arylformyl-amine amino-hydrolase EC 3.5.1.9) which promotes transfer of a formyl group from N-formyl-L-kynurenine to the amino group of the substrate (Santii & HopsuHavu, 1968) . Should rapid acetylators of AG also prove to be rapid formylators, then the tendency for N-formylation to be reduced in rapid acetylators (cf. nitroG) would be counteracted by more rapid formylation of the smaller pool of AG, resulting in no net reduction of Nformylation in the rapid, as compared with the slow acetylators.
As a result of the present demonstration that AG is polymorphically acetylated, patients are now routinely typed for acetylator status (using sulphadimidine) before starting AG therapy. Moreover, since patients are treated chronically, i.e. they are given daily doses of 1 g, as opposed to the single 250 mg dose given to the volunteers, plasma levels will be monitored during therapy to see whether these differ between the acetylator phenotypes, despite the evidence that they do not vary significantly after a single dose. These proposed studies should enable a retrospective assessment of any influence of acetylator phenotype upon the magnitude and duration of response, as well as on the nature and duration of side effects, and may guide the selection of patients for AG therapy, as well as the design of analogues with improved therapeutic benefit.
